Upper GI Cancer Research Report Site Specific Group Meeting Friday 29th January 2016
Cancer specialty specific objectives Recruitment overall at 20% of cancer incidence Recruitment to interventional studies at 7.5% of cancer incidence Recruiting local portfolio to include: Surgical trials (4 recruits per 100,000 pop) Rare cancers (12 recruits per 100,000 pop) Children and young people (3 recruits per 100,000 pop) Radiotherapy (6 recruits per 100,000 pop)
Studies recruiting 2015-16
New studies in set up pending NHS permission for consideration locally SCALOP-2 - A multi-centre randomised study of induction chemotherapy followed by capecitabine (+/-nelfinavir) with high or standard dose radiotherapy for locally advanced non-metastatic pancreatic cancer. Closure date: November 2019 ACTICCA-1 - Adjuvant chemotherapy with gemcitabine and cisplatin compared to observation after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma (ACTICCA-1 trial) A randomized, multidisciplinary, multinational AIO/DGAV/DGVS phase III trial. Closure date: August 2018
Contact maxine.taylor@nihr.ac.uk UGI SSG and CRN: West of England Research Lead Contact maxine.taylor@nihr.ac.uk
Contact & reference details Maxine.taylor@nihr.ac.uk – Research Delivery Manager Hugh.barr@glos.nhs.uk – Network Cancer Clinical Lead http://csg.ncri.org.uk/portfolio-maps/ - for detailed list of whole UGI portfolio including links to eligibility criteria https://www.edge.nhs.uk/Account/Index?ReturnUrl=%2f http://www.crn.nihr.ac.uk/can-help/funders-academics/nihrcrn-portfolio/